Partner with Myriad™
Meet the demands of complex soft-tissue reconstruction
Join a national network of independent sales professionals supporting surgeons in trauma, plastics, and complex wound reconstruction with Myriad’s third-generation bioscaffold solution.
Why partner with AROA?
As demand grows for effective solutions in complex soft-tissue defects, Myriad offers experienced sales professionals the opportunity to partner with a trusted organization to unlock regenerative healing for everybody.
At AROA, we help you focus on selling by providing training and access to reimbursement, medical affairs, billing, marketing, and logistical resources.
Whether you’re looking to expand your portfolio or represent a full surgical bag, Myriad offers flexible 1099 opportunities designed to fit your needs.
The Myriad Difference
Designed for use in complex surgical wounds and soft-tissue defects.
Nationwide GPO Coverage
We are listed on all major GPOs, including Vizient, Premier, HealthTrust, and Ascension, ensuring broad national access to our products.
Ongoing Support
From training and billing to reimbursement support and insurance verification, we offer ongoing services to all our 1099 partners and customers.
Prospective Clinical Trial - LIVE
Myriad has been described in peer-reviewed clinical literature, including a recent publication in Journal of Trauma and Injury (January 2026) evaluating its use in vascularized tissue coverage for trauma and acute care surgery defects.
Versatile Defect Applications
Myriad is available in multiple configurations and sizes to accommodate a wide range of complex soft-tissue defects while helping minimize wastage.
Efficient Application Profile
Hospital-Ready Portfolio
Built to align with hospital processes, contracting expectations, and standardized use.
100+ Peer Reviewed Publications
Myriad’s platform technology, AROA ECM, has been studied across a variety of clinical specialties and complex soft tissue deficits.
24
Pre-clinical peer-reviewed publications
81
Peer-reviewed clinical publications
Founded in 2008, AROA is ethically minded and dedicated to unlocking regenerative healing for everybody
Our products are approved for use in over 50 countries
7.6+ million devices used in clinical applications worldwide
Four product families spanning all sites of care
World-leading outcomes
Backed by compelling clinical evidence our products support world-leading outcomes in functional tissue regeneration, even in the most complex wounds.
Widespread impact
Designed for widespread impact, our products are versatile, accessible, and simple to use.
Unmatched value
Our products deliver unmatched value by reducing hospital costs and driving meaningful operational improvements.
Think AROA is a good fit for you?
Complete the form to register your expression of interest to partner with us. We will only use your information to assess your application and we will not share your information without your approval.
Don’t delay, get in early and make sure you are ready for the change.
By submitting this application, you agree that your application will be accepted or declined at AROA’s sole discretion, and acknowledge that AROA will have no liability to you in relation to this application process.
References
1. Lun, S et al. Biomaterials. 2010;31(16):4517-4529.
2. Bohn G A et al. J Wound Care. 2020;29(12):742-749.
3. Cormican M T et al. Eplasty. 2023;23:e66.
4. Chaffin A E et al. J Wound Care. 2020;29(11):624-630.
5. Chaffin A E et al. J Wound Care. 2021;30(Sup7):S28-S34.
6. Bosque B A et al. Int Wound J. 2022;19(4):741-753.
7. Lawlor J et al. Plast Reconstr Surg Glob Open. 2024;12(12):e6406.
8. Dempsey, S G et al. PLoS One. 2020;15(7):e0235784.
